ERBB2 and breast carcinoma: A recent study [8] which defined HER2-amplified breast cancers with m17 as CEP17 signals < 1.5 per nucleus and HER2/CEP17 ratio ≥ 2.0 showed that outcomes of such trastuzumab-treated patients was similar to other HER2 positive patients.